These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36660542)

  • 1. Correlation Between Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms and Renal Function in Elderly Men Aged 80 Years and Older.
    Wang Q; Zhang B; Li B; Yang S; Wang Z; Han C; Wu J; Tian R
    Clin Interv Aging; 2023; 18():61-69. PubMed ID: 36660542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
    BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
    Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy.
    Bauer SR; Walter LC; Ensrud KE; Suskind AM; Newman JC; Ricke WA; Liu TT; McVary KT; Covinsky K
    JAMA Netw Open; 2021 Nov; 4(11):e2134427. PubMed ID: 34817584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    De Nunzio C; Salonia A; Gacci M; Ficarra V
    World J Urol; 2020 Nov; 38(11):2771-2779. PubMed ID: 32060633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of HT080 for lower urinary tract symptoms associated with benign prostatic hyperplasia: A study protocol for a randomized, double-blind, placebo-controlled trial.
    Song J; Lee SH; Kim H
    Medicine (Baltimore); 2019 Nov; 98(45):e17848. PubMed ID: 31702643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
    Roehrborn CG; Egan KB; Miner MM; Ni X; Wong DG; Rosen RC
    BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolically healthy obesity is associated with increased risk of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A cohort study of Chinese elderly males.
    Chen W; Man S; Wang B; Kadeerhan G; Huang X
    Low Urin Tract Symptoms; 2022 May; 14(3):170-177. PubMed ID: 34882977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Breyer BN; Huang WY; Rabkin CS; Alderete JF; Pakpahan R; Beason TS; Kenfield SA; Mabie J; Ragard L; Wolin KY; Grubb RL; Andriole GL; Sutcliffe S
    BJU Int; 2016 Jan; 117(1):145-54. PubMed ID: 25601300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced sleep duration increases the risk of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in middle-aged and elderly males: a national cross-sectional study.
    Xiong Y; Zhang Y; Zhang F; Wu C; Qin F; Yuan J
    Aging Male; 2022 Dec; 25(1):159-166. PubMed ID: 35635060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
    Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
    Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential role of glutathione S-transferase P1 gene polymorphism and metabolic syndrome in lower urinary tract symptoms attributed to benign prostatic hyperplasia.
    Zhang W; Li Z; Liu M; Mu Y; He J; Chen P; Liu D; Chen K; Che B; Xu S; Zhang H; Tang K
    World J Urol; 2021 Dec; 39(12):4413-4419. PubMed ID: 34228163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials.
    Vlachopoulos C; Oelke M; Maggi M; Mulhall JP; Rosenberg MT; Brock GB; Esler A; Büttner H
    Int J Clin Pract; 2015 Dec; 69(12):1496-507. PubMed ID: 26299520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
    AbdelRazek M; Abolyosr A; Mhammed O; Fathi A; Talaat M; Hassan A
    World J Urol; 2022 Aug; 40(8):2063-2070. PubMed ID: 35773357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms.
    Lee YC; Juan YS; Liu CC; Bao BY; Wang CJ; Wu WJ; Huang CN; Huang SP
    BJU Int; 2016 Aug; 118(2):313-9. PubMed ID: 26940040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of lower urinary tract symptoms associated with benign prostatic hyperplasia in elderly patients with a new diagnostic, therapeutic and care pathway.
    Carbone A; Fuschi A; Al Rawashdah SF; Al Salhi Y; Velotti G; Ripoli A; Autieri D; Palleschi G; Pastore AL
    Int J Clin Pract; 2016 Sep; 70(9):734-43. PubMed ID: 27561366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of increased urine brain derived neurotrophic factor with lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Wang LW; Li JL; Yu Y; Xiao RH; Huang HW; Kuang RR; Hai B
    J Huazhong Univ Sci Technolog Med Sci; 2017 Aug; 37(4):531-535. PubMed ID: 28786061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Zhang J; Li X; Yang B; Wu C; Fan Y; Li H
    World J Urol; 2019 Jan; 37(1):143-153. PubMed ID: 29948047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.